Can Down Syndrome Be Screened via IVF in Thailand? PGT-A Embryo Screening Principles and Process Explained
Direct Answer Down syndrome (trisomy 21) can be screened for in embryos using Thailand's third-generation IVF technology, namely PGT-A (Preimplantation Genetic Testing for Aneuploidy). This technology can detect whether an embryo has an abnormal number of chromosome 21, allowing for the selection of chromosomally normal embryos for transfer. However, it must be clarified: PGT-A is a screening technology with certain limitations and is not applicable in all cases.
Genetic Basis of Down Syndrome
Down syndrome is the most common autosomal trisomy disorder, caused by an extra copy of chromosome 21. The vast majority of cases (approximately 92%) originate from maternal meiotic nondisjunction, with a smaller proportion arising from paternal origin or post-fertilization division errors. The older the female age at conception, the higher the risk of meiotic nondisjunction in oocytes—risk increases significantly after age 35 and further escalates after age 40.
From an embryonic perspective, Down syndrome is a chromosomal numerical abnormality, not a single-gene mutation. This means that the presence of trisomy 21 can be determined by detecting the copy number of chromosomes in the embryo. PGT-A technology is based on this principle, screening embryos at the chromosomal level.
PGT-A Screening Principle and Accuracy
PGT-A (Preimplantation Genetic Testing for Aneuploidy) involves a micro-biopsy of embryonic cells, using high-throughput sequencing (NGS) or gene chip technology to analyze chromosomal copy numbers and determine if the embryo is aneuploid. The testing target is typically the blastocyst on day 5-6, with biopsy of trophectoderm cells (which will develop into the placenta), without directly damaging the inner cell mass (which will develop into the fetus).
Testing Accuracy
| Parameter | Reference Range | Explanation |
|---|---|---|
| Sensitivity (detecting trisomy 21) | Approximately 96%–99% | Varies slightly between laboratories and technology platforms |
| Specificity (classifying as normal) | Approximately 98%–99.5% | False positive rate approximately 0.5%–2% |
| Ability to detect mosaicism | Partially detectable | Low-level mosaicism (<20%) may be missed |
| Limitations | Cannot detect structural rearrangements, single-gene disorders | Requires combination with other testing methods |
Core Conclusion: PGT-A can significantly reduce the probability of transferring an embryo with Down syndrome, but it cannot achieve 100% exclusion. Very low-level mosaicism or platform errors may lead to false negatives or false positives.
Practical Process of PGT-A Screening in Thailand
For PGT-A screening in Thailand, most reproductive centers use technology platforms synchronized with Europe and the US. The overall process can be divided into the following stages:
- Pre-assessment and Genetic Counseling: Both partners undergo chromosomal karyotyping, carrier screening, infectious disease testing, and ovarian reserve assessment (AMH, FSH, antral follicle count). The doctor evaluates suitability for PGT-A and explains the scope and limitations of screening.
- Ovarian Stimulation and Egg Retrieval: Ovarian stimulation is performed according to an individualized protocol, lasting approximately 10–14 days, followed by transvaginal ultrasound-guided egg retrieval.
- IVF and Blastocyst Culture: Fertilization is achieved via IVF or ICSI, and embryos are cultured to the blastocyst stage on day 5-6. An adequate number of blastocysts is the foundation for PGT-A.
- Embryo Biopsy: For blastocysts meeting biopsy criteria, an opening is made in the zona pellucida, and 3–5 trophectoderm cells are aspirated.
- Genetic Testing: The biopsied sample is sent for testing, typically using an NGS platform, with a testing period of approximately 7–14 days.
- Cryopreservation and Transfer: After results are available, chromosomally normal blastocysts are selected for frozen-thawed embryo transfer (FET). Endometrial preparation is required before transfer.
From starting the cycle to obtaining test results usually takes 6–8 weeks. If waiting for all results before transfer, the total cycle is approximately 2–3 months.
Characteristics of PGT-A in Thailand
| Aspect | Explanation |
|---|---|
| Technology Platform | Primarily NGS; some centers use aCGH or SNP array |
| Biopsy Timing | Blastocyst stage biopsy on day 5-6 post-fertilization |
| Testing Scope | Whole chromosome aneuploidy (including chromosome 21) + some centers can simultaneously detect large chromosomal deletions/duplications |
| Embryo Number Requirement | At least 3–5 blastocysts recommended for biopsy to increase the probability of obtaining a normal embryo |
| Legal Regulation | Thailand has no explicit prohibition against PGT-A; compliant reproductive centers can perform it |
Doctor's Perspective: Screening Limitations and Considerations
Clinically, patients often have overly high expectations of PGT-A, believing that screening guarantees a healthy child. As a reproductive physician, it is necessary to objectively explain the following limitations:
- Mosaicism Issue: Approximately 2%–5% of embryos have chromosomal mosaicism (mixture of normal and abnormal cells). The biopsy sample may not fully represent the true chromosomal status of the entire embryo. Low-level mosaicism can lead to misdiagnosis.
- Testing Error: Due to factors such as technology platform, laboratory quality control, and number of biopsied cells, there is a 0.5%–2% risk of false positive or false negative results.
- Cannot Cover All Genetic Diseases: PGT-A only detects chromosomal numerical abnormalities and cannot screen for single-gene disorders (e.g., thalassemia, cystic fibrosis) or chromosomal structural rearrangements (e.g., balanced translocations).
- Risk of No Embryo for Transfer: For patients of advanced age or with diminished ovarian reserve, all embryos may be aneuploid, resulting in no embryo available for transfer.
- Potential Impact of Biopsy on Embryo: Although blastocyst biopsy technology is quite mature, any procedure carries potential risks, including a minor impact on embryonic developmental potential.
Note: PGT-A is a screening tool, not a diagnostic tool. Prenatal diagnosis (e.g., amniocentesis) is still recommended after pregnancy to confirm the fetal chromosomal status.
Special Situations and Assessment of Suitable Candidates
Individuals Suitable for PGT-A Screening
- Women aged ≥35 years, especially those ≥38 years planning pregnancy
- History of pregnancy with Down syndrome or chromosomal abnormality
- One partner is a carrier of a balanced translocation or Robertsonian translocation
- Recurrent miscarriage (≥2) of unknown cause
- Severe male factor infertility (sometimes associated with chromosomal abnormalities)
- Families wishing to reduce the risk of chromosomal abnormality pregnancy
Relatively Unsuitable or Requiring Careful Evaluation
- Very poor ovarian reserve (AMH <0.5 ng/mL, antral follicles <3), low egg yield, low probability of forming blastocysts
- Very low blastocyst formation rate (<20%) in previous IVF cycles
- Limited financial resources, unable to afford the additional cost of PGT-A (approximately 30,000–60,000 RMB, varying by center)
- Ethical or religious concerns regarding embryo biopsy
Frequently Asked Questions
For the detection rate of trisomy 21, mainstream NGS platforms can achieve over 98%. However, it is important to understand that "accuracy" includes both sensitivity and specificity. Clinically, the more relevant point is: an embryo screened as normal still has approximately a 1%–2% chance of having a chromosomal abnormality (including mosaicism). Therefore, prenatal diagnosis is still recommended after transfer.
From the initial consultation to completing a full cycle (ovarian stimulation + biopsy + testing + frozen embryo transfer) usually takes 2–3 months. The ovarian stimulation phase takes about 2 weeks, blastocyst culture 5–6 days, testing period 7–14 days, and endometrial preparation about 2–4 weeks.
Blastocyst-stage biopsy, performed by experienced embryologists, has minimized damage to the embryo. Current evidence-based medical data shows that transferring euploid embryos after PGT-A results in implantation rates not significantly different from high-quality non-biopsied blastocysts, and may even improve single transfer success rates due to the selection of normal embryos.
Even with normal chromosomes in both partners, eggs and sperm can still randomly undergo meiotic nondisjunction, leading to embryonic aneuploidy. Advanced maternal age is a major risk factor. Therefore, even if the couple's karyotype is normal, PGT-A still has screening value, especially when the woman is aged ≥35 years.
PGT-A costs vary by center, testing platform, and number of embryos tested. The approximate range: embryo biopsy fee + testing fee is about 30,000–60,000 RMB (per cycle, including 3–5 embryos). This does not include ovarian stimulation medication, egg retrieval surgery, cryopreservation, and transfer costs. Most centers charge incrementally based on the number of embryos; exceeding the base number incurs additional fees. It is advisable to request a detailed breakdown during consultation.
Practitioner Observation: Differences Between PGT-A in Thailand and China
As a practitioner who has interacted with multiple reproductive centers, I have observed the following characteristics of PGT-A in Thailand:
- Earlier Technology Adoption: Some Thai centers began large-scale NGS-PGT implementation around 2012, resulting in relatively mature laboratory experience.
- Different Policy Environment: Thailand has more relaxed regulations on embryonic genetic testing compared to China, with no strict restrictions on the applicable population for PGT-A, allowing for more flexible clinical decision-making.
- Differences in Embryo Culture Strategies: Thai centers commonly use time-lapse incubators combined with AI morphological assessment to assist in selecting biopsy timing.
- Need for Self-Assessment: The quality of reproductive centers in Thailand varies. Some smaller clinics may not have independent genetics laboratories and may send samples to third-party testing facilities, requiring extra attention to quality control standards.
When choosing PGT-A in Thailand, it is recommended to focus on: whether the laboratory has independent genetic testing qualifications, embryologist biopsy experience, data quality control systems, and supporting genetic counseling services. It is not advisable to decide based solely on the marketing concept of "third-generation IVF." Instead, request specific test report templates, platform information, and success rate data from the center.
Time Planning Reminder
PGT-A involves embryo biopsy and testing, making the process more complex than conventional IVF. Uncontrollable time factors include:
- Variability in ovarian stimulation response: Poor ovarian response may prolong stimulation days or lead to cycle cancellation.
- Blastocyst formation rate: Approximately 30%–60% of fertilized eggs develop to blastocysts; insufficient numbers may affect biopsy decisions.
- Testing period: Different testing platforms have varying report turnaround times, ranging from 7–14 days.
- Endometrial preparation cycle: If additional hysteroscopy or endometrial testing is needed, it may add 1–2 months.
Individuals with specific time constraints (e.g., work leave, age factors) are advised to plan ahead and allow for flexibility. A total cycle of 3–4 months is generally recommended for greater certainty.
Doctor's Advice: For embryonic screening of Down syndrome, PGT-A is currently one of the most effective early intervention methods available. However, every technology has its boundaries—screening is not a guarantee, and a normal embryo does not guarantee pregnancy. Viewing PGT-A as a risk reduction tool rather than an absolute safeguard, combined with prenatal diagnosis to form a closed-loop management, is the rational decision-making path.
This content is written based on general knowledge of assisted reproductive medicine and is for reference only. Specific plans must be evaluated and formulated by a registered reproductive physician based on individual medical conditions. It does not constitute medical advice or a diagnostic commitment.
